The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

Lung Cancer Test Predicts Survival in Early Stages Better Than Current Methods ... that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations ...

The team from Cancer Research UK's Manchester Institute says it has created a new in vitro model of lung squamous cell ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...

This paper explores the potential of mitochondrial-associated programmed-cell-death (mtPCD) patterns as biomarkers for ...

In Sharmila Tagore’s cancer case, early detection was the game changer. Her story serves as both a cautionary tale and a ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

Cancer Research scientists have developed a new cell-based model of lung squamous cell carcinoma (LUSC), a type of lung cancer, which has the potential to develop more effective treatments for the ...

In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...